Publications by authors named "David J Porter"

Claim this Profile
T
The younger women's wellness after cancer program: results from feasibility testing in Aotearoa New Zealand (the 'Kōwhai study').
Janine P Porter-Steele, Katrina J Sharples, Bobbi B Laing, Sarah Benge, Sarah M Balaam, David J Porter

Support Care Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.
Halle C F Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre, David J Porter

J Natl Cancer Inst· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do medical procedures in the arm increase the risk of lymphoedema after axillary surgery? A review.
Chris-Tin Cheng, Jessica M Deitch, Ian E Haines, David J Porter, Sharon L Kilbreath

ANZ J Surg· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pre-steady state and steady state kinetic analysis of the N-ribosyl hydrolase activity of hCD157.
Frank Preugschat, Luke H Carter, Eric E Boros, David J T Porter, Eugene L Stewart

Arch Biochem Biophys· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The base exchange reaction of NAD+ glycohydrolase: identification of novel heterocyclic alternative substrates.
Frank Preugschat, Ginger H Tomberlin, David J T Porter

Arch Biochem Biophys· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
Curt D Haffner, Caroline J Diaz, Aaron B Miller, Robert A Reid, Kevin P Madauss, David J T Porter

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
Mary H Hanlon, David J T Porter, Eric S Furfine, Andrew Spaltenstein, H Luke Carter

Biochemistry· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzymatic activities of the GB virus-B RNA-dependent RNA polymerase.
C T Ranjith-Kumar, Jan Lee Santos, Lester L Gutshall, Victor K Johnston, Juili Lin-Goerke, David J Porter

Virology· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Michael F Maguire, Rosario Guinea, Philip Griffin, Sarah Macmanus, Robert C Elston, David J T Porter

J Virol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 protease: characterization of a catalytically competent enzyme-substrate intermediate.
David J T Porter, Mary H Hanlon, Eric S Furfine

Biochemistry· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
Huw D Thomas, David J Porter, Imke Bartelink, Joy R Nobbs, Michael Cole

Br J Clin Pharmacol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis